Official Title
COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study
Brief Summary

Given the current lack of effective COVID-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. The modes of person-to-person transmission of SARS-CoV-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. SARS-CoV-2 can also be transmitted directly or indirectly through saliva. The use of antiviral mouthrinses may be used as adjunctive therapy.

Completed
COVID19
Mouthwash
Saliva

Device: mouthrinse with bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

Device: mouthrinse without bêta-cyclodextrin and citrox

3 daily mouthrinses for 7 days

Eligibility Criteria

Inclusion Criteria:

- Clinical diagnosis of Covid-19 infection by the patient's general practitioner and
hospital doctor

- Clinical signs started less than 8 days ago.

- Virological confirmation

- Understanding and acceptance of the trial.

- Written agreement to participate in the trial

Exclusion Criteria:

- Pregnancy

- Breastfeeding

- Inability to comply with protocol

- Lack of written agreement

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: 85 Years
Countries
France
Locations

Clinic of the Protestant Infirmary in Lyon
Caluire-et-Cuire, France

Hospital Center Emile Roux
Le Puy en Velay, France

Hospital Center Saint Luc Saint Joseph
Lyon, France

Intercommunal Hospital Center of Mont de Marsan
Mont de Marsan, France

Florence Carrouel, Dr, Study Director
University Claude Bernard Lyon 1

Hospices Civils de Lyon
NCT Number
Keywords
COVID19
SARS-CoV-2
mouthrinses
Antiviral
bêta-cyclodextrin
citrox
MeSH Terms
COVID-19
Betadex